Anna Lantsova

Anna Lantsova

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LNLudmila Nikolaeva
Ludmila Nikolaeva
NONatalia Oborotova
Natalia Oborotova
NBNatalia Bunyatyan
Natalia Bunyatyan
XZXi Zhang
Xi Zhang
ESEkaterina Sanarova
Ekaterina Sanarova
APAlevtina Polozkova
Alevtina Polozkova
Despite the rapid development of medical technologies, chemotherapy treatment still occupies an important place in clinical oncology. In this regard, the current research in this area focuses on the synthesis of new highly effective antitumor substances that have minimal side effects and the development of stable pharmaceutical formulations (PF) on their basis. In order to solve this problem, the I. Ya. Postovsky Institute of Organic Synthesis of the Ural Branch of the Russian Academy of Sciences actively sought for original substances, namely, nitrosourea (NU) derivatives, one of the most promising classes of anticancer drugs. As a result of this research, a novel NU derivative was synthesized, namely ormustine, which showed high antitumor activity in preliminary preclinical trials. It is now crucial to develop an ormustine pharmaceutical formulation. Conducted technological studies showed that the most suitable solvent for the drug substance is 0.1 M hydrochloric acid, which ensures its rapid dissolution by ultrasonic treatment. A significant reduction in the concentration of the active ingredient during the storage of the solution required the development of a technique of its lyophilization and the selection of a shaper such as a Kollidon 17 PF. Upon completion of the development of a pharmaceutical formulation of ormustine, its stability after lyophilization was demonstrated, and a sufficient amount of the drug has been acquired for preclinical research.

31 October 2022 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
EIE. V. Ignatieva
E. V. Ignatieva
IYI. V. Yartseva
I. V. Yartseva
ZSZoya Shprakh
Zoya Shprakh
AKA. P. Kolpaksidi
A. P. Kolpaksidi
MDM. V. Dmitrieva
M. V. Dmitrieva
IPI. R. Prosalkova
I. R. Prosalkova
Background. A glycoside derivative of indolocarbazole LHS-1269, one of the new drugs selectively affecting tumors, which was first synthesized at the N.N. Blokhin National Medical-Research Center of Oncology of the Ministry of Health of Russia, is of particular scientific interest. Experimental studies demonstrated a multi-target mechanism of action of this compound. LHS-1269 interacts with several intracellular targets and induces various pathways of cell death. Several innovative models of the dosage forms were designed to achieve the highest antitumor activity of the compound and to perform further preclinical studies.Aim. To develop the methods for the quantitative determination of LHS-1269 in pharmaceutical compositions proposed as a result of the search for the optimal dosage form.Materials and methods. The study analyzed the spectrophotometric characteristics of LHS-1269 solutions in dimethylformamide, dimethylsulfoxide (DMSO) and in the mixture of solvents DMSO–ethyl alcohol, as well as electronic absorption spectra of the excipients in the mixture of solvents DMSO–ethyl alcohol. Spectrophotometric measurements were performed on a Cary 100 spectrophotometer (Varian, Inc., Australia) in the wavelength range from 200 to 500 nm. The standard sample is the substance LHS-1269 (N.N. Blokhin Oncology Research Center of the Ministry of Health of Russia).Results. The carried out studies showed that LHS-1269 solutions in dimethylformamide, DMSO and mixture of DMSO– ethyl alcohol are suitable for spectrophotometric measurements. Several variants of the methodology for the assay of LHS-1269 in various dosage form models that differ in the content of the active substance and the excipients composition have been developed: LHS-1269 concentrate for solution for injection and infusion; lyophilisate for solution for injection; liposomal lyophilisate for dispersion for injection.Conclusion. Techniques for the assay of LHS-1269 in dosage form models have been developed. It has been shown that the developed techniques are applicable for LHS-1269 quantitative determination in innovative dosage forms containing polymeric low molecular weightsolubilizers, lipids, cholesterol, mono- or oligosaccharides as excipients.

30 June 2015 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
ALAnna Lantsova
Anna Lantsova
EKE. A. Kotova
E. A. Kotova
ESE. V. Sanarova
E. V. Sanarova
APA. P. Poloskova
A. P. Poloskova
MBM. A. Baryshnikova
M. A. Baryshnikova
АЛАнна Владимировна Ланцова
Анна Владимировна Ланцова
His study objective has been to develop optimal composition of Cifelin sterically stabilized liposomal formulation. The substance of Cifelin synthesized in chemical synthesis laboratory FSBNI «N.N. Blokhin RCRC». All used excipients and reagents conform to the standard documentation. Method of obtaining liposomes includes: a method of obtaining Cifelin multilamellar and unilamellar liposomes dispersions. Liposomal dispersion has been lyophilized on freeze-dryer Edwards Minifast DO.2. Liposomes size has been measured by light diffusion dynamic spectrums copy on Nicomp 380 Submicron Particle Sizer. Quantitative measurement has been conducted by spectrometry in ultraviolet area. Crystals of unenclosed into lipid bilayer Cifelin have been separated by filtration through filter with pore diameter of 0,22 μm. Lipids peroxidation has been estimated by concentration of oxidation final product - MDA. MTT-test has been used to estimate Cifelin LF cytotoxic activity in vitro. In this study the optimum molar ratio of components has been found for liposomal membrane composed of phosphatidylcholine, cholesterol and DSPE-PEG-2000. Composition with lipids molar ratio 165 : 8 : 1 and “lipid: Cifelin” ratio 12 : 1 has been chosen as optimal by entrapment efficiency and appearance, encapsulated API value in this composition has been 98±1 %, liposomal size has been 136±12 nm. On cell line SKOV-3 and Jurkat in vitro cytotoxic effect of Cifelin liposomal drug form has been highly increased. As a result of the study drug product “Cifelin lyophilized liposomal for injections 17 mg” has been developed.

1 January 2012 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
ALAnna Lantsova
Anna Lantsova
EKE. Kotova
E. Kotova
KSK. Sanarova
K. Sanarova
NON. Oborotova
N. Oborotova
APA. Poloskova
A. Poloskova
VKV. Krasnov
V. Krasnov

14 June 2022 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
MKMarina P. Kiseleva
Marina P. Kiseleva
LBLarisa M. Borisova
Larisa M. Borisova
GSGalina B. Smirnova
Galina B. Smirnova
YBYulia A. Borisova
Yulia A. Borisova
ALAnna Lantsova
Anna Lantsova
MKMarina V. Komarova
Marina V. Komarova
Introduction: The creation of highly effective original anticancer drugs remains an urgent direction of scientific research in tumor therapy. One of the promising groups in this regard is indolocarbazoles and their derivatives, which are capable of initiating various pathways of tumor cell death. The aim of the study was to evaluate an antiproliferative activity of a new, Russian derivative of N-glycoside substituted indolocarbazole 6-amino-12-(α-L-arabinopyranosyl)indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione (LCS-1208) on models of transplantable tumors of mice and on human tumors in Balb/c nude mice. Materials and methods: Indolocarbazole sensitivity to LCS-1208 was assessed on transplantable tumors of mice – lymphatic leukemia L-1210, cervical carcinoma (CC-5), and colon adenocarcinoma (CAC) by five-fold intraperitoneal administration (ip) of the LCS-1208 substance in single doses of 50, 75, 100 mg/kg. Investigation into the effectiveness of the LCS-1208 lyo dosage form was performed on subcutaneous xenografts of human colon cancer SW620 by an in­travenous administration (iv). The antitumor effect was evaluated by the tumor growth inhibition (TGI) and an increase in life span (ILS) of the treated animals as compared with the control ones. Evaluation of specific antitumor activity on xenografts was performed according to the tumor/control (T/C%) criterion (maximum criterion T/C≤42%). Results and discussion: According to the results of the study, the most sensitive to the action of the LCS-1208 sub­stance in the case of an ip administration of a total dose of 375 mg/kg were CAC with TGI=97–62%, p≤0.001 up to 16 days after the treatment, and ILS=36% (criteria for TGI≥70% and ILS≥25%). On xenografts of a human colon cancer SW620, the effectiveness of the LCS-1208 lyo drug dosage form within the range of total doses from 50 to 150 mg/kg in case of iv to Balb/c nude mice was set at T/C = 35–2% (criterion T/C<42%). Conclusion: The presented results suggest possible effectiveness of LCS-1208 in treatment of colon malignant tumors of humans.

23 November 2023 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
ESEkaterina Sanarova
Ekaterina Sanarova
ALAnna Lantsova
Anna Lantsova
LNLudmila Nikolaeva
Ludmila Nikolaeva
VOVasiliy Osipov
Vasiliy Osipov
DGD. V. Gusev
D. V. Gusev
LBL. M. Borisova
L. M. Borisova
Background. Increasing the solubility of new pharmacologically active substances is one of the main tasks of pharmacy. It becomes even more relevant in the field of creating dosage forms for difficult-to-solubilise substances with a new mechanism of action, as in the case of 3-hydroxyquinazoline derivatives, which have shown in vivo experiments the ability to activate tumour cell death by ferroptosis. This includes OVF-009 – an original domestic substance. Due to the solubility of this compound in oils, the technology of its solubilisation using modified castor oil (Kolliphor® ELP, BASF, Germany), approved for parenteral use, was proposed.Aim. To create a model dosage form for a new hydrophobic quinazoline derivative in order to further evaluate the spectrum of its antitumour activity in in vivo experiments.Materials and methods. OVF-009, Kolliphor® ELP, 95 % ethanol, Kollidon 17 PF (BASF, Germany), sodium hydroxide, phosphate buffer, water for injection; spontaneous micelle formation, ultrasound, potentiometry, dynamic light scattering, electrophoretic method, viscometry method, etc.Results. The main properties of micelle-forming solubiliser Kolliphor® ELP and its aqueous solutions were considered; 10 model solutions OVF-009 based only on Kolliphor® ELP and with addition of ethanol and Kollidon 17PF in different concentrations were obtained; the quality of the obtained compositions was evaluated by parameters – appearance, solution transparency, pH, stability over time and tolerability by laboratory animals. As a result, two formulations prepared on phosphate buffer were chosen: formulation No 5, which contains 10 % Kolliphor® ELP and additionally 10 % polyvinylpyrrolidone, and formulation No 8, in which in addition to the main solubiliser 10 % ethanol and 16 % polyvinylpyrrolidone were added. Both formulations have neutral pH, can be stored for 24 h and are tolerated by laboratory animals.Conclusion. The selected model compositions for solubilisation of the substance OVF-009 on the basis of Kolliphor® ELP allowed to provide the concentration of the active substance in the solution suitable for further biological experiments on animals.